
(Thanks to Dr. Prabhat Saha for the research project I assisted him on, which brought this litigation and its details to my attention and led me to write this post.)
“Where the patentee has no intention of working the invention in this country…or is otherwise not interested in working the invention in India, the grant of the Indian patent might tend to improve the economy of the patentee’s home country but offers little advantage to us.”
— Justice Ayyangar, 1959
In early 2024, families of Cystic Fibrosis patients wrote a letter to the government. The letter asked the Department for Promotion of Industry and Internal Trade (DPIIT) to use the Patents Act to make the drug affordable. Rs 2.66 crore, that was the price put on Trikafta. Trikafta is a fixed dose combination (FDC) of 3 drugs– Elexacaftor, Ivacaftor, & Tezacaftor, and one of the necessary drugs for treatment of people suffering with Cystic Fibrosis. More than two and a half years later, nothing has changed.
On 19 November 2026, the Delhi High Court will hear Vertex Pharmaceuticals’ appeal, Vertex Pharmaceuticals Incorporated vs Assistant Controller Of Patents And Designs & Anr. (C.A.(COMM.IPD-PAT) 22/2026) against the Indian Patent Office’s rejection of its patent application IN 202017037860. (See here) The application covers a fixed-dose combination co-formulating three drugs, Elexacaftor, Ivacaftor and Tezacaftor, which in effect makes it a claim on Trikafta itself. It is only one of Vertex’s filings, but it sits on top of a larger story: a company with layers of patents, almost no sales in India, and no consequences. This post follows that story in order: the patent term the litigation is really about, the non-working behind it, and the failed attempts to break through.
One Treatment, Nine Filings
Trikafta is not a single molecule but a combination of three, so generics can lawfully enter only once every patent standing in front of that combination has run out, and a single expiry date therefore misleads. The table below sets out all nine of Vertex’s filings in India for these molecules, what each one claims and when it ends.
| Patent /Application | What it covers | Status | Expiry | Date of International Filing |
| IN 282654 | Ivacaftor compound | Granted 2017 | 24 Jun 2025 (expired) | 24 Jun 2005 |
| IN 272379 | Tezacaftor series of compounds | Granted 2016 | 9 Apr 2027 | 9 Apr 2007 |
| IN 2423/KOLNP/2014 | Tezacaftor intermediates and processes (divisional of the IN 272379 application) | Abandoned 2019 | None | 9 Apr 2007 |
| IN 383370 | Ivacaftor spray-dried formulation | Granted 2021 | 27 Feb 2033 | 27 Feb 2013 |
| IN 566019 | Broad genus of CFTR modulator compounds | Granted 2025 | 6 Oct 2035 | 6 Oct 2015 |
| IN 202538029975 | Divisional of IN 566019: genus compounds co-formulated with Tezacaftor and Ivacaftor | Under examination | 6 Oct 2035, if granted | 6 Oct 2015 |
| IN 558135 | Elexacaftor compound | Granted 2025 | 8 Dec 2037 | 8 Dec 2017 |
| IN 559486 | Elexacaftor polymorphs and salts (divisional of IN 558135) | Granted 2025 | 8 Dec 2037 | 8 Dec 2017 |
| IN 202017037860 | Elexacaftor, Tezacaftor and Ivacaftor tablet | Refused 28 Jan 2026, appeal pending | 4 Feb 2039, if granted | 4 Feb 2019 |
Reading throughout, the table shows protection is stacked rather than simply extended. IN 282654, the Ivacaftor compound patent, has already expired, yet the combination stays blocked by IN 272379 on Tezacaftor until 9 April 2027, by IN 383370 on the Ivacaftor formulation until 27 February 2033, by the broad genus patent IN 566019 until 6 October 2035 and, last of all, by the two Elexacaftor patents, IN 558135 and IN 559486, until 8 December 2037, with one Tezacaftor divisional, IN 2423/KOLNP/2014, abandoned along the way in 2019.
Vertex has also gone after the combination itself, which is why two of these filings matter most. IN 202538029975, a divisional of IN 566019 filed on 28 March 2025, just 39 days before the parent was granted, seeks the genus compounds co-formulated with Tezacaftor and Ivacaftor and is still under examination, while IN 202017037860 claims the Elexacaftor, Tezacaftor and Ivacaftor tablet directly and is the application now before the Delhi High Court.
On 28 January 2026, after a pre-grant opposition by Balaji R., the Assistant Controller refused IN 202017037860 solely for lack of inventive step under Section 25(1)(e) read with Section 2(1)(ja). (See here) The Controller held that earlier documents had already hinted at combining these drugs. Those documents were a 2016 patent application (WO 2016/057572), and the 2017 trial disclosures. The Controller also said that simply mixing crystalline Elexacaftor with existing Tezacaftor and Ivacaftor formulations using ordinary ingredients, was the kind of routine adjustment any pharmaceutical technician would make. Since Vertex was unable to show any data the combination worked better than the three drugs taken separately, the Controller concluded it was a simple modification, not one involving inventive steps. The other opposition grounds, including Section 3(e), were formally rejected as not independently established, but that lack of composition-level synergy went straight to the heart of the inventive-step refusal.
The sharper finding concerned inherited inventiveness: Vertex argued that because Elexacaftor is itself patented (IN 558135), any tablet containing it inherits that inventiveness, but the Controller refused to let one patent carry another where the prior art already suggested the combination, and Vertex consequently appealed under Section 117A of the Patents Act before the Delhi High Court.
So why does this one application matter? Would anything change if the Delhi High Court upholds the refusal? Would the patent term held by Vertex come down from 2037 to anything earlier? No, since the Elexacaftor patents (IN 558135 and IN 559486) already run until 8 December 2037, and affirming the refusal leaves the effective patent term exactly where it is. But if the refusal is reversed, IN 202017037860, with a PCT filing date of 4 February 2019, would run until 4 February 2039, which is 14 more months of exclusivity on the exact tablet patients take. That is a grave prospect when the patentee is not working its patents and when generic entry is further held back by the government’s reluctance to use the tools the Act provides.
The Patent Term is Not the Only Problem
But the patent term is only part of the problem, because Vertex has really sold so little of its patented medicines in India. Its Form 27 statements for IN 282654, the Ivacaftor patent, report 9 imported units worth Rs 96.31 lakh in 2018-19 and 12 units worth Rs 1.2 crore in 2019-20, roughly Rs 10 lakh a unit. Due to the 2020 Patent Rules amendments, the Form 27 filings 2020 onwards disclosed patents being worked with only revenue being reported and no units. The Form 27 filings reported revenue of Rs 85.63 lakh in 2020-21, and Rs 32.31 lakh in 2021-22 from direct patient sales of Orkambi, with no sales at all in 2022-23, while the Tezacaftor patent, IN 272379, was declared not worked every year from 2017 to 2025 for want of the regulatory approval that never came, and the Ivacaftor formulation patent, IN 383370, was also reported not worked. Critical to note here that the 2020 onwards Form 27 filings highlight dilution of the working disclosure regime, discussed later, shows that one doesn’t have one of the crucial pieces of information–number of units sold, to understand if reasonable requirements of the public have been satisfied or not, which is a ground for CL under section 84.
CDSCO’s SUGAM portal tells the same story: my searches returned “No Results Found” for tezacaftor, elexacaftor and vanzacaftor, and for ivacaftor, whose compound patent expired in June 2025, the approvals belong to the Indian generic companies MSN Laboratories and Laurus Labs (the latter also had approvals for combination of ivacaftor with lumacaftor), with none for Vertex. (See compilation of my searches here) The patients’ letter disclosed that identified CF patients in India were at 600 to 1,200, with the number going up to 40,000 likely, meanwhile there is no government record which provides a specific number. However, even against the disclosed number of patients, and their need, the record shows very few imported units and two generic approvals.
This is a case where a patent is being held rather than worked, which Section 83(b) forbids by providing that patents are not granted merely to give an import monopoly, and which is exactly what Justice Ayyangar warned against. The Act counters non-working with a compulsory licence under Section 84, which requires three years from grant (open now for IN 272379 and IN 383370, though not yet for the Elexacaftor patents since granted in early 2025), revocation under Section 66, or action by the Union under Sections 92 and 100, none of which has a three-year wait, and yet none has been used against these patents.
That inaction exposes two failures, the first being evidence, because every remedy above runs on Form 27 and the disclosure system was failing long before this case. Late Prof. Shamnad Basheer’s 2015 PIL surveyed about 270 filings across 150 patents and found that over 35% of patentees filed nothing between 2009 and 2012, with no action ever taken under Section 122, and although the Delhi High Court ordered reform on 23 April 2018, what followed was dilution. (see here) Prof. Prabhat Saha and Shivam Kaushik show how the 2020 amendments replaced exact figures with approximate revenue and a short note, and the Patents (Amendment) Rules, 2024 went further with filing once every three years, a tick box for “worked” with no revenue, no declaration on whether public needs are met, and a note that import alone cannot make a patent “not worked”. (See here) The second failure is one of will, and it is visible in what patients have been asked to endure.
Patients Without Access
Patients did not wait for the courts to act; their early 2024 letter to the DPIIT Secretary listed the prices, with Kalydeco at Rs 21 lakh, Symdeko at Rs 2.14 crore, Orkambi at Rs 2.25 crore and Trikafta at Rs 2.66 crore, and asked for government use under Section 100 or a licence under Section 92, or else revocation under Section 66. It also noted that the National Rare Diseases Policy 2021 (see chapter 13) envisages local manufacture and that the Health Ministry had not asked the DPIIT to act on it. Despite the representation, no substantive action followed.
The courts became the next recourse, and on 19 March 2024 three CF patients, filed Writ Petition, Ms. X and Ors. v. Union of India & Ors. (W.P. 9920/2024) in the Karnataka High Court seeking the same relief. (See here) On 3 July 2025, Justice M. Nagaprasanna directed that they be evaluated at the Indira Gandhi Institute of Child Health, Bengaluru, with funds released within 15 days, but that relief was only interim, and the core question still remains undecided after more than two years, with the petition merely released from part-heard to the regular roster bench on 19 August 2026. (See here)
Meanwhile, on 23 May 2025, the Union of India, the main respondent, filed a transfer petition titled Union of India v. Parents of Children Suffering from Rare Genetic Disorder Diseases in State of Karnataka (T.P.(C) 1763-1764/2025) in the Supreme Court, which was listed on 4 July 2025 before Justices Pamidighantam Sri Narasimha and R. Mahadevan is still pending, so that the case asking the Union to use its own powers is now stuck behind the Union’s own petition. Though the Supreme Court docket neither shows any order passed in the petition, nor it provides details as to what is the transfer petition regarding and to what court or bench etc. (See here)
With respect, the courts have not done enough here, because this is a case that calls for urgency, one that treats access to a life-saving medicine as an emergency and not as a roster item. The Supreme Court recognised as much In Re: Access to Life-Saving Medicines and Judicial Expediency in Article 21 Matters (SMW(C) 19/2026), where it directed the Kerala High Court to decide the Ribociclib matter, In Re: Exorbitant Pricing of Life Saving Patented Medicines (W.P.(C) 18999/2022) expeditiously, (see here) and the Kerala High Court affirmed that non-commercial state procurement under Section 100 rests on Articles 21 and 47. (See here; here; here) The bottom line is simple, even if the lives of ten patients hang on a decision, that should be enough, and here the facts are plain: a patentee not working its patents, a statute full of remedies, and a government not using them.
A Regime Hollowed Out
So, is there new hope? A refusal upheld on 19 November would stop the patent term from stretching to 2039, yet it would not put a tablet in a child’s hands. That is the real lesson here. The case Cystic Fibrosis is not an exception, rather another example of how far India’s patent regime has been diluted. The provisions which were envisioned to secure access in exactly these situations, working requirements, compulsory licences, revocation, government use and the Form 27 disclosures that feed them, remain on the statute book, but they no longer work, made redundant. Moreover, as recently discussed by Arnav as well, there is rising discourse for introducing data exclusivity framework as well in India. A pro-public health interest regime that helped build India’s pharmaceutical industry and earn it the name pharmacy of the world has been diluted again and again, and Trikafta and Ribociclib are the epitome of what that dilution looks like in practice.
Reading and writing about this, it is hard not to feel helpless. For a patient, or a parent quoted Rs 2.66 crore, it must be far worse. Sadly, this is the state of access to patented medicines in India.
